Ten63 Therapeutics Announces Collaboration with Boehringer Ingelheim for Drug Discovery – Draper Decentralized – 5.31.24
Ten63 Therapeutics, a biotechnology company specializing in advanced AI and physics-based models to tackle undruggable diseases, has partnered with Boehringer Ingelheim for multi-target drug discovery. This collaboration aims to develop new therapeutic molecules for diseases that conventional methods have not been able to treat, addressing significant unmet patient needs.